Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Post-Traumatic Headache
NCT03806985Phase 1Terminated
- Sponsor
- Yale University
- Start
- Mar 2019
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in post-traumatic headache (PTH) (6 arms), sponsored by Yale University. Primary endpoints: Acute change in pain intensity at 24 hours, Acute change in nausea/vomiting at 24 hours and 8 more. Started Mar 2019; status: terminated.
02
Drugs
psilocybin
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT03806985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806985.